BR112014017426A8 - formulação de quitosana glicada viscoelástica, método para o tratamento do câncer, composição, imunoadjuvante, e, método para destruir a neoplasia de forma fotofísica, e ao mesmo tempo gerar uma vacina autóloga in situ - Google Patents

formulação de quitosana glicada viscoelástica, método para o tratamento do câncer, composição, imunoadjuvante, e, método para destruir a neoplasia de forma fotofísica, e ao mesmo tempo gerar uma vacina autóloga in situ

Info

Publication number
BR112014017426A8
BR112014017426A8 BR112014017426A BR112014017426A BR112014017426A8 BR 112014017426 A8 BR112014017426 A8 BR 112014017426A8 BR 112014017426 A BR112014017426 A BR 112014017426A BR 112014017426 A BR112014017426 A BR 112014017426A BR 112014017426 A8 BR112014017426 A8 BR 112014017426A8
Authority
BR
Brazil
Prior art keywords
immunoadjuvant
neoplasm
situ
composition
formulation
Prior art date
Application number
BR112014017426A
Other languages
English (en)
Other versions
BR112014017426B1 (pt
BR112014017426A2 (pt
Inventor
Raker Joseph
Waynant Kristopher
Alleruzzo Luciano
Jenkins Peter
Carubelli Raoul
Nordquist Robert
Hode Tomas
Chen Wei
Original Assignee
Immunophotonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48799808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014017426(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunophotonics Inc filed Critical Immunophotonics Inc
Publication of BR112014017426A2 publication Critical patent/BR112014017426A2/pt
Publication of BR112014017426A8 publication Critical patent/BR112014017426A8/pt
Publication of BR112014017426B1 publication Critical patent/BR112014017426B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Otolaryngology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Electromagnetism (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1 / 1 resumo “formulaã‡ãƒo de quitosana glicada viscoelãstica, mã‰todo para o tratamento do cã‚ncer, composiã‡ãƒo, imunoadjuvante, e, mã‰todo para destruir a neoplasia de forma fotofãsica, e ao mesmo tempo gerar uma vacina autã“loga in situ” o presente invento refere-se genericamente a composiã§ãµes terapãªuticas compreendendo composiã§ãµes de derivados de quitosana, sã£o usadas em conexã£o com mã©todos para o tratamento de neoplasmas, como ã© o caso dos neoplasmas malignos do pulmã£o, tirã³ide e rim, de outros tipos de tumores malignos, e de outras desordens mã©dicas.
BR112014017426-1A 2012-01-20 2013-01-17 Formulação de quitosana glicada viscoelástica, composição farmacêutica, composição e imunoadjuvante BR112014017426B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261588783P 2012-01-20 2012-01-20
US61/588,783 2012-01-20
PCT/US2013/021903 WO2013109732A2 (en) 2012-01-20 2013-01-17 Chitosan-derived compositions

Publications (3)

Publication Number Publication Date
BR112014017426A2 BR112014017426A2 (pt) 2017-06-13
BR112014017426A8 true BR112014017426A8 (pt) 2017-07-04
BR112014017426B1 BR112014017426B1 (pt) 2021-12-28

Family

ID=48799808

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017426-1A BR112014017426B1 (pt) 2012-01-20 2013-01-17 Formulação de quitosana glicada viscoelástica, composição farmacêutica, composição e imunoadjuvante

Country Status (30)

Country Link
US (1) US20150018748A1 (pt)
EP (2) EP3831393A1 (pt)
JP (1) JP6180436B2 (pt)
KR (5) KR20200139254A (pt)
CN (2) CN110038125A (pt)
AU (1) AU2013209716B2 (pt)
BR (1) BR112014017426B1 (pt)
CA (1) CA2861367C (pt)
CL (1) CL2014001880A1 (pt)
CO (1) CO7101239A2 (pt)
CY (1) CY1123490T1 (pt)
DK (1) DK2804611T3 (pt)
EA (1) EA030148B1 (pt)
EC (1) ECSP14014778A (pt)
ES (1) ES2829899T3 (pt)
HK (1) HK1210019A1 (pt)
HR (1) HRP20201647T1 (pt)
HU (1) HUE051744T2 (pt)
IL (1) IL233649B (pt)
LT (1) LT2804611T (pt)
MX (1) MX371275B (pt)
MY (1) MY191932A (pt)
NZ (1) NZ628433A (pt)
PE (1) PE20142325A1 (pt)
PL (1) PL2804611T3 (pt)
PT (1) PT2804611T (pt)
RS (1) RS61257B1 (pt)
SG (1) SG11201403943TA (pt)
SI (1) SI2804611T1 (pt)
WO (1) WO2013109732A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
US11111316B2 (en) * 2012-01-20 2021-09-07 Immunophotonics, Inc. Chitosan-derived compositions
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
CN107200788B (zh) * 2017-05-11 2020-04-14 暨南大学 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
US20200010575A1 (en) * 2018-07-05 2020-01-09 Immunophotonics, Inc. Semi-synthetic biopolymers for use in treating proliferative disorders
WO2020060131A1 (ko) * 2018-09-19 2020-03-26 주식회사 엘지화학 LiOH를 포함하는 리튬 이차 전지용 전극, 그의 제조방법, 및 상기 전극을 포함하는 리튬 이차 전지
EP3817773A4 (en) 2018-11-26 2021-09-15 Forty Seven, Inc. HUMANIZED ANTIBODIES AGAINST C-KIT
WO2023028311A1 (en) * 2021-08-27 2023-03-02 Immunophotonics, Inc. Glycated chitosans for treatment of viral infections
WO2024133580A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Medical products containing an aqueous formulation of a peptide
WO2024133588A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Compositions comprising an oncolytic peptide and chitosan

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US591200A (en) 1897-10-05 Safe-lock
US4424346A (en) * 1981-06-04 1984-01-03 Canadian Patents And Development Ltd. Derivatives of chitins, chitosans and other polysaccharides
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5214036A (en) 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5283225A (en) 1992-11-24 1994-02-01 Eastman Kodak Company Underlayer of dye-donor element for thermal dye transfer systems
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
US6316007B1 (en) * 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
WO1996031237A2 (en) * 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
JP4606586B2 (ja) * 1998-11-10 2011-01-05 株式会社ネーテック 機能性キトサン誘導体
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US20040047892A1 (en) * 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
US6756363B1 (en) * 2000-11-17 2004-06-29 Wound Healing Of Oklahoma, Inc. Solutions and films of glycated chitosan
US20110130473A1 (en) * 2007-11-13 2011-06-02 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers
CN101440136B (zh) * 2008-12-12 2011-07-06 中国海洋大学 胺糖化几丁聚糖复合物的制备方法

Also Published As

Publication number Publication date
EP2804611B1 (en) 2020-09-30
PT2804611T (pt) 2020-11-12
AU2013209716B2 (en) 2017-04-27
CN104619310A (zh) 2015-05-13
CA2861367C (en) 2021-06-29
PE20142325A1 (es) 2015-02-01
RS61257B1 (sr) 2021-01-29
CO7101239A2 (es) 2014-10-31
BR112014017426B1 (pt) 2021-12-28
LT2804611T (lt) 2020-11-25
SG11201403943TA (en) 2014-08-28
ECSP14014778A (es) 2016-01-29
BR112014017426A2 (pt) 2017-06-13
WO2013109732A2 (en) 2013-07-25
CL2014001880A1 (es) 2014-11-07
MY191932A (en) 2022-07-19
CN110038125A (zh) 2019-07-23
CY1123490T1 (el) 2022-03-24
US20150018748A1 (en) 2015-01-15
KR20220028153A (ko) 2022-03-08
PL2804611T3 (pl) 2021-03-08
EP2804611A2 (en) 2014-11-26
IL233649A0 (en) 2014-08-31
MX2014008702A (es) 2015-04-08
EA201491402A1 (ru) 2014-12-30
JP2015513522A (ja) 2015-05-14
EP2804611A4 (en) 2016-02-17
KR20170032490A (ko) 2017-03-22
HUE051744T2 (hu) 2021-03-29
EA030148B1 (ru) 2018-06-29
AU2013209716A1 (en) 2014-08-28
NZ628433A (en) 2017-02-24
WO2013109732A3 (en) 2015-01-08
HK1210019A1 (en) 2016-04-15
CA2861367A1 (en) 2013-07-25
KR20200139254A (ko) 2020-12-11
DK2804611T3 (da) 2020-11-09
JP6180436B2 (ja) 2017-08-16
HRP20201647T1 (hr) 2021-06-25
SI2804611T1 (sl) 2021-01-29
EP3831393A1 (en) 2021-06-09
MX371275B (es) 2020-01-23
KR20140117487A (ko) 2014-10-07
KR20180123727A (ko) 2018-11-19
IL233649B (en) 2019-07-31
ES2829899T3 (es) 2021-06-02

Similar Documents

Publication Publication Date Title
BR112014017426A2 (pt) formulação de quitosana glicada viscoelástica, método para o tratamento do câncer, composição, imunoadjuvante, e, método para destruir a neoplasia de forma fotofísica, e ao mesmo tempo gerar uma vacina autóloga in situ
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
EP4140487A8 (en) Combination therapy for treating cancer
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
BR112015022588A2 (pt) composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
MX2015011583A (es) Derivados de amatoxina.
AU2018270408A1 (en) Methods of inhibiting aging and treating aging-related disorders
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
GB201209613D0 (en) New compounds
WO2014194254A9 (en) Treatment of cancers using pi3 kinase isoform modulators
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
BR112015011147A8 (pt) composto, composição farmacêutica, e, uso do referido composto
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
UA116053C2 (uk) Застосування похідних бензоімідазолу-проліну
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado
CY1122935T1 (el) Ενισχυτικα της υδατοδιαλυτοτητας που βασιζονται στο γλυκογονο

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/01/2013, OBSERVADAS AS CONDICOES LEGAIS.